CarePathRx

Overview

CarePathRx is the health-system pharmacy services arm of Cigna Group’s Evernorth, operating after Evernorth moved to full ownership in 2026. It helps hospitals and IDNs operate specialty pharmacy, home and ambulatory infusion, 340B support, telepharmacy, GPO / purchasing, transition-of-care, and medication-management workflows; the operating hub traces back to the 2020 UPMC Chartwell partnership and pharmacy carve-out. Buyers searching Chartwell or UPMC Chartwell should evaluate CarePathRx as the current operator.

CarePathRx is not a national LDD specialty pharmacy network and not a hub services operator. It is a health-system pharmacy platform: most relevant when the access strategy depends on hospital-owned specialty pharmacy, infusion site-of-care, 340B-covered-entity coordination, or an IDN partner that can support complex patients after discharge.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, CarePathRx is evaluated as health-system pharmacy services arm of Cigna Group’s Evernorth, operating after Evernorth moved to full ownership in 2026.

Capability	Buyer should compare	CarePathRx readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Health-system centered. Strongest where dispensing flows through hospital / IDN partners and integrated specialty pharmacy programs, not where a manufacturer only needs broad retail-specialty reach.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Coverage workflow. Evaluate handoffs among the health system, CarePathRx operating teams, Evernorth assets, and any external hub or field reimbursement partner.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Strong engagement model. Medication-management, telepharmacy, patient-therapy-management, and transition-of-care workflows are central to the platform.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Infusion-adjacent fit. Best suited to therapies where hospital specialty pharmacy, home infusion, ambulatory infusion, or provider coordination matter. Validate product-specific REMS and temperature-control scope in the RFP.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Platform-enabled but diligence-heavy. Ask for exact data feeds, cadence, EHR touchpoints, abandonment definitions, and governance around Evernorth / payer-affiliated data use.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Main differentiator. CarePathRx belongs on the shortlist when the manufacturer needs health-system pharmacy, home / ambulatory infusion, 340B, and transition-of-care coordination in one operating model.

Buyer Fit

• Program fit: Brands needing a health-system channel partner for specialty pharmacy, infusion, 340B coordination, discharge-to-home care, or IDN pharmacy capture.
• Therapy and product fit: Stronger fit for oncology, immunology, rare disease, infectious disease, IVIG, biologics, and other therapies where specialty pharmacy and infusion workflows intersect with hospital care.
• Commercial fit: Use an RFP-led process that defines health-system coverage, launch geographies, data rights, service levels, escalation paths, and integration with the manufacturer’s hub or PSP.
• Profile signal: CarePathRx is most useful when the brand’s channel design values hospital-owned specialty pharmacy and site-of-care flexibility more than a pure national specialty-pharmacy network.
• Data diligence: Confirm LDD eligibility, payer access, 340B treatment, hub handoffs, patient consent flow, reporting cadence, Evernorth data governance, and whether services are bundled or available modularly.

Differentiators

• Health-system specialty pharmacy plus home and ambulatory infusion in the same operating model.
• 340B, telepharmacy, transition-of-care, and medication-management support for hospital partners.
• ProCure GPO and delivery/logistics coordination for specialty and home-infusion products.
• Technology stack spanning centralized order review, patient therapy management, hospital EHR integration, and patient mobile engagement.
• Evernorth ownership creates adjacency to Accredo and broader specialty-care assets, while also requiring explicit payer-affiliation diligence.

RFP Questions

• Which named health-system partners and geographies can support this product at launch?
• How can CarePathRx access the product as an LDD pharmacy, through a health-system partner, through infusion, or only through a support-services role?
• How are benefit investigation, prior authorization, financial assistance, hub handoffs, and patient consent divided among CarePathRx, the health system, Evernorth assets, and the manufacturer’s existing partners?
• What dispense, abandonment, adherence, infusion, and outcomes data will be delivered, at what cadence, and with what payer-affiliated data-use restrictions?
• How are 340B claims, contract-pharmacy rules, replenishment, chargeback, and covered-entity responsibilities governed?
• Which services are modular versus bundled with broader health-system pharmacy management?

Recent Activity

• Jan 2025 - Nashville General Hospital specialty pharmacy partnership.
• Jun 2025 - ProCure by CarePathRx announced an exclusive SDS Rx partnership for home-infusion and specialty-pharmacy delivery support.
• Jul 2025 - Oregon Health Authority transaction notice process surfaced Evernorth’s acquisition of the remaining CarePathRx interest.
• Feb-Mar 2026 - Public reporting described Evernorth / Cigna moving to full ownership of CarePathRx.
• Apr 2026 - Randy Hyun was announced as Executive in Residence at Frazier Healthcare Partners.